The main findings of this retrospective study were that individuals identified as dGHD had lower IGF-1 concentrations at baseline, with a higher increase after 1 year of treatment, and had a higher prevalence of pathological retesting and overweight/obesity at the end of treatment. The gene discussed is IGF1; the disease is Obesity.